1Ossandon A,Cassaara E A M,Priori R,et al.Thalidomide:focus on its employment in rheumatic disease.Clin Exp Rheumatol,2002,20(5):709
2Bariol C,Meagher A P,Vickers C R,et al.Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.J Gastroenterol Hepato1,2002,17 (2):135
3Moreira A L,Sampaio E P,Zmuidzinas A,et al.Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing Dredge operatormRNA degredation.J Exp Med,1993,177(6):1675
4Corral L.Differential cytokine modulation and T cell activation by 2 distinct classes of thalidomide analogues that are potent inhibitors of TNF -α.J Immunol,1999,163(1):380
5Geitz H.thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.Immunopharmacology,1996,31 (2):213
6Dredge K,Marriott J B,Todryk S M,et al.Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th-1 type immunity.J Immunol,2002,168 (10):4914
7Oliver S J.The Th1/Th2 paradigm in the pathogenesis of scleroderma and its modulation by thalidomide.Curr Rheumatol,2000,2 (6):486
8Keifer J A,Guttridge D C,Ashburner B P,et al.Inhibition of NF-kB activity by thalidomide through suppression of IkB kinase activity.J Biol Chem,2001,276(25):22382
2S. Singhal,J. Mehta,Thalidomide in cancer,Biomed Pharmacother,2002,56(1): 4-12.
3Macpherson GR, Franks M, Tomoaia-Cotisel A et al. Current status of thalidomide and its role in the treatment of metastatic prostate cancer[J].Critical Reviews in Oncology/Hematology,2003,46:S49-/S57
4Bisacchi D, Benelli R, Vanzetto C et al.Anti-angiogenesis and angioprevention:mechanisms,problems and perspectives[J].Cancer Detection and Prevention,2003,27(3):229-38.
5Musto P. Thalidomide therapy for myelodysplastic syndromes:current status and future perspectives[J].Leukemia Research,2004,28(4):325-32.
6Kenyon BM, Fiona Browne, D'amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization[J].Exp Eye Res,1997,64(6):971-8.
7Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent[J].Biochemical Pharmacology,1998,55(11):1827-34.
8Myounga H, Hongb SD, Kima YY et al.Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma[J].Cancer Letters,2001,163(2):191-200.
9Amato RJ. Thalidomide therapy for renal cell carcinoma,Critical Reviews in Oncology/Hematology,2003,46:S59-/S65.
